Healthcare Services

Global Neurological Biomarkers Market Set for Strong Expansion Reaching $22.81 Billion by 2030 at 14% CAGR

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Neurological Biomarkers Market Expected To Change Between 2026 And 2030?

The neurological biomarkers market has experienced significant expansion recently. It is projected to grow from $11.92 billion in 2025 to $13.52 billion in 2026, maintaining a compound annual growth rate (CAGR) of 13.4%. This historical growth can be attributed to the rising prevalence of neurological disorders, early development of protein biomarkers, increased use of imaging biomarkers, growing adoption of dna biomarkers, and initial integration of biomarkers in clinical trials.

The neurological biomarkers market is anticipated to undergo significant expansion over the next few years. It is projected to achieve a value of $22.82 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.0%. This growth throughout the forecast period can be primarily linked to the increasing utilization of biomarker-based personalized medicine, a rising demand for metabolomics biomarkers, heightened investment in central nervous system (CNS) drug development, the creation of next-generation diagnostic platforms, and the expanding application of biomarker-driven disease monitoring. Notable trends within the forecast period encompass the growing use of biomarkers in early neurological diagnosis, increased adoption of proteomic and genomic biomarkers, the broadening application of imaging biomarkers in CNS disorder evaluation, a rising need for biomarkers in drug development pipelines, and an intensifying clinical focus on testing for neurodegenerative disease biomarkers.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp

Which Major Factors Are Driving The Expansion Of The Neurological Biomarkers Market?

The growing occurrence of neurological diseases is set to boost the expansion of the neurological biomarker market in the coming years. Neurological illnesses affect the brain, spinal cord, and all other nerves throughout the body. Parkinson’s disease is a neurodegenerative disorder that impacts the neurological system and the parts of the body controlled by nerves. Neurological biomarkers assist in the early diagnosis of Parkinson’s disease through pathological, biochemical, and genetic testing. For instance, in October 2023, the World Federation of Neurology, a UK-based charity, indicated an accelerating global health burden, noting that neurological disorders are now the second-leading cause of death and the primary cause of disability worldwide, with over 40 percent of the global population affected in 2023, and the number of individuals living with brain disease is projected to nearly double by 2050. Consequently, the increasing prevalence of neurological diseases is fueling the growth of the neurological biomarker market.

How Is The Neurological Biomarkers Market Structured Across Different Segments?

The neurological biomarkers market covered in this report is segmented –

1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products

2) By Application: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy

3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users

Subsegments:

1) By Proteomics Biomarker: Protein Biomarkers, Antibody Biomarkers

2) By Genomics Biomarker: DNA Biomarkers, RNA Biomarkers

3) By Metabolomics Biomarker: Metabolite Biomarkers, Lipid Biomarkers

4) By Imaging Biomarker: MRI Biomarkers, PET Scan Biomarkers

5) By Other Products: Neuroinflammatory Biomarkers, Neurotransmitter Biomarkers

Which Trends Are Impacting The Growth Of The Neurological Biomarkers Market?

Leading companies active in the neurological biomarkers market are innovating new products like advanced biomarker blood tests to gain a competitive advantage in the sector. Biomarker blood tests involve examining specific molecules or indicators in the blood that provide information about a biological condition, disease, or physiological process. For instance, in July 2023, Quanterix Corporation, a US-based company specializing in the development and commercialization of ultra-sensitive digital immunoassay platforms, launched the LucentAD biomarker blood test. The LucentAD test is designed to assist medical professionals in evaluating patients who exhibit cognitive symptoms consistent with preliminary indications of alzheimer’s disease. The test quantifies levels of p-Tau 181, which has been established as a biomarker for the pathophysiology of alzheimer’s disease (AD). When an adult is being tested for AD 1 and has cognitive impairment, the LucentAD test findings are intended to be used as a diagnostic tool. This test is not meant to be used as a stand-alone screening or diagnostic assay and must be utilized in conjunction with other diagnostic tools.

Which Major Players Dominate The Neurological Biomarkers Market?

Major companies operating in the neurological biomarkers market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

Read the full neurological biomarkers market report here:

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Which Region Currently Holds The Largest Share Of The Neurological Biomarkers Market?

North America was the largest region in the neurological biomarkers market in 2025. The regions covered in the neurological biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurological Biomarkers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12677&type=smp

Browse Through More Reports Similar to the Global Neurological Biomarkers Market 2026, By The Business Research Company

Genomics Global Market Report

https://www.thebusinessresearchcompany.com/report/genomics-global-market-report

Neurological Biomarkers Global Market Report

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Neuroscience Global Market Report

https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795